Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Stock Rated “Hold” by Wall Street Analysts

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) has been assigned a consensus rating of “Hold” from the five brokerages that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $6.00.

CTXR has been the subject of several recent analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Citius Pharmaceuticals in a report on Monday, September 21st. Citigroup reiterated a “buy” rating on shares of Citius Pharmaceuticals in a research note on Wednesday, August 19th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Citius Pharmaceuticals in a research report on Wednesday, August 19th.

Institutional Investors Weigh In On Citius Pharmaceuticals

A hedge fund recently bought a new stake in Citius Pharmaceuticals stock. BlackRock Inc. purchased a new position in shares of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 69,850 shares of the company’s stock, valued at approximately $42,000. BlackRock Inc. owned approximately 0.25% of Citius Pharmaceuticals at the end of the most recent quarter. 16.88% of the stock is currently owned by institutional investors.

Citius Pharmaceuticals Trading Down 2.2%

NASDAQ:CTXR opened at $0.55 on Monday. The business has a 50 day moving average of $0.53 and a 200 day moving average of $0.65. The company has a debt-to-equity ratio of 0.08, a quick ratio of 0.40 and a current ratio of 0.84. Citius Pharmaceuticals has a 1-year low of $0.37 and a 1-year high of $1.54.

Citius Pharmaceuticals (NASDAQ:CTXR) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.02. As a group, research analysts anticipate that Citius Pharmaceuticals will post -2.03 earnings per share for the current fiscal year.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for critical care, oncology and other areas with significant unmet medical needs. The company is headquartered in Cranford, New Jersey, and has primarily focused its development and commercialization activities on the U.S. healthcare market.

Citius’ lead product candidate has been Mino-Lok, an antibiotic lock solution designed to help salvage infected central venous catheters by treating catheter-related bloodstream infections while allowing the catheter to remain in place.